文献速递糖尿病

利钠肽作为1型糖尿病全因死亡及心肾并发症风险标志物的比较

Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2020-12-15

该研究在664例1型糖尿病患者中比较MR-proANP与NT-proBNP对全因死亡、心血管及肾脏结局的预测价值。NT-proBNP翻倍独立关联全因死亡、心血管复合终点、心衰及肾脏复合终点;MR-proANP关联所有终点但不独立于NT-proBNP。

要点

  • NT-proBNP翻倍独立预测1型糖尿病全因死亡、心衰及心肾复合终点
  • MR-proANP的关联在校正NT-proBNP后均失去显著性
  • 两者均与eGFR下降≥30%无关联

核心结论

  • 较高的NT-proBNP独立关联全因死亡、心血管疾病、心衰和肾脏复合终点。
  • MR-proANP关联除eGFR下降外的所有终点,但不独立于NT-proBNP。
  • MR-proANP可能有助于NT-proBNP在1型糖尿病风险分层中的预测价值。

研究设计与样本

  • 在664例1型糖尿病患者中测量MR-proANP与NT-proBNP。
  • 评估NT-proBNP或MR-proANP每翻倍的风险比(HR),校正心血管危险因素并互相加入模型。
  • 中位随访5.1-6.2年。

主要发现

  • MR-proANP关联全因死亡(n=57;HR 1.7,95%CI 1.1-2.7)、心血管复合终点(n=94;1.6,1.1-2.2)、心衰(n=27;2.8,1.5-5.2)、肾脏复合终点(n=123;1.6,1.2-2.1)和ESKD(n=21;3.1,1.2-7.8),校正心血管危险因素后P≤0.02。
  • 加入NT-proBNP后MR-proANP对所有终点的显著性均丧失。
  • NT-proBNP翻倍关联全因死亡(HR 1.5,95%CI 1.2-1.8)、心血管复合终点(1.3,1.1-1.5)、心衰(1.7,1.3-2.1)和肾脏复合终点(1.3,1.1-1.4),独立于心血管危险因素(模型2 P<0.001)和MR-proANP(模型3 P≤0.03)。
  • NT-proBNP与eGFR下降≥30%(n=93)无关联。

临床怎么用

  • 在1型糖尿病风险分层中可优先关注NT-proBNP作为心肾并发症与死亡的风险标志物。
  • MR-proANP单独使用价值有限,可考虑与NT-proBNP联合评估。
  • 两者均不适用于预测eGFR下降≥30%。

局限性

  • 样本量664例,部分终点事件数较少(如ESKD n=21、心衰n=27)。
  • 随访时间较短(中位5.1-6.2年)。
  • 观察性设计不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Few studies have compared midregional proatrial natriuretic peptide (MR-proANP) and N-terminal probrain natriuretic peptide (NT-proBNP). We compared their value as risk markers for all-cause mortality and cardiovascular (CV) and renal complications in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: MR-proANP and NT-proBNP were measured in 664 individuals. Hazard ratios (HRs) were assessed per doubling of NT-proBNP or MR-proANP for risk of a composite of ischemic events, heart failure (HF), a combined renal end point of end-stage kidney disease (ESKD), decline in estimated glomerular filtration rate (eGFR) ≥30%, and all-cause mortality or individual end points. Adjustments included CV risk factors and addition of MR-proANP or NT-proBNP. RESULTS: Median follow-up was 5.1-6.2 years. MR-proANP was associated with higher risk of all-cause mortality (n = 57; HR 1.7, 95% CI 1.1-2.7), combined CV end point (n = 94; 1.6, 1.1-2.2), HF (n = 27; 2.8, 1.5-5.2), combined renal end point (n = 123; 1.6, 1.2-2.1), and ESKD (n = 21; 3.1, 1.2-7.8) independent of CV risk factors (P ≤ 0.02). After addition of NT-proBNP, significance for all end points was lost. A doubling of NT-proBNP was associated with higher risk of all-cause mortality (HR 1.5, 95% CI 1.2-1.8), the combined CV end point (1.3, 1.1-1.5), HF (1.7, 1.3-2.1), and the combined renal end point (1.3, 1.1-1.4) independent of CV risk factors (model 2 [P < 0.001]) and MR-proANP (model 3 [P ≤ 0.03]). There was no association with decline in eGFR ≥30% (n = 93). CONCLUSIONS: Higher NT-proBNP was independently associated with all-cause mortality, CV disease, HF, and the combined renal end point. MR-proANP was associated with all end points but decline in eGFR, although not independent of NT-proBNP. MR-proANP may contribute to the predictive value of NT-proBNP for risk stratification in type 1 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tofte N, Theilade S, Winther SA, et al. Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care. 2020. PMID: 33323477. doi:10.2337/dc20-2107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。